Benznidazole biotransformation in rat heart microsomal fraction without observable ultrastructural alterations: Comparison to Nifurtimox-induced cardiac effects

Memorias do Instituto Oswaldo Cruz

Volumn 103, Issue 6, 2008, Pages 549-553

  Montalto De Mecca, María ^a   Bartel, Laura C ^a   Rodríguez De Castro, Carmen ^a   Castro, José A ^a  

^a Centro de Investigaciones Toxicologicos   (Argentina)

Author keywords

Benznidazole; Cardiopathy; Chagas disease; Nifurtimox; Nitroreduction

Indexed keywords

RATTUS;

EID: 54349119199     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/s0074-02762008000600007     Document Type: Article

References (25)

1. Bartel LC, Montalto de Mecca M, Fanelli SL, Rodríguez de Castro C, Díaz EG, Castro JA 2007. Early Nifurtimox-induced biochemical and ultrastructural alterations in rat heart. Hum Exp Toxicol 26: 781-788.
2. Castro JA, Montalto de Mecca M, Bartel LC 2006. Toxic side effects of drugs used to treat Chagas' disease (American Trypanosomiasis). Hum Exp Toxicol 25: 471-479.
3. Coura J, de Castro SL 2002. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 97: 3-24.
4. de Castro CR, de Toranzo EGD, Castro JA 1992. Benznidazole-induced ultrastructural alterations in rat adrenal cortex. Mechanistic studies. Toxicology 74: 223-232.
5. Díaz EGD, de Castro CR, de Mecca MM, Castro JA 2000. Benznidazole-induced ultrastructural and biochemical alterations in the rat colon. Acta Pharmacol Sin 21: 961-966.
6. Docampo R, Moreno SN 1985. Biochemical toxicology of antiparasitic compounds used in the chemotherapy and chemoprophylaxis of American Trypanosomiasis (Chagas' disease). Rev Biochem Toxicol 7: 159-204.
7. Elbekai RH, El-Kadi AO 2006. Cytochrome P450 enzymes: Central players in cardiovascular health and disease. Pharmacol Ther 112: 564-587.
8. Fabbro de Suasnábar D, Arias E, Streiger M, Piacenza M, Ingaramo M, Del Barco M, Amicone N 2000. Evolutive behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated chronic chagasic patients. Rev Inst Med Trop São Paulo 42: 99-109.
9. Fabbro DL, Streiger ML, Arias ED, Bizai ML, del Barco M, Amicone NA 2007. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. Rev Soc Bras Med Trop 40: 1-10.
10. Gad SC 2001. Statistics for toxicologists. In AW Hayes, Principles and methods of toxicology, 4th ed., Taylor & Francis, Philadelphia, USA, p. 285-364.
11. Gallerano RR, Sosa RR 2000. Interventional study in the natural evolution of Chagas' disease. Evaluation of specific antiparasitic treatment. Retrospective-prospective study of antiparasitic theraphy. Rev Fac Cien Med Univ Nac Cordoba 57: 135-162.
12. García S, Ramos CO, Senra JF, Vilas-Boas F, Rodrigues MM, Campos de Carvalho AC, Ribeiro dos Santos R, Soares MB 2005. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations. Antimicrob Agents Chemother 49: 1521-1528.
13. Gillette JR, Davies DC, Sasame HA 1972. Cytochrome P450 and its role in drug metabolism. Annu Rev Pharmacol 12: 57-84.
14. Gorla N, Diaz Gomez MI, Castro JA 1986. Interaction of benznidazole reactive metabolitos with rat liver deoxyribonucleic acid and nuclear proteins. Arch Int Pharmacodyn Ther 280: 22-31.
15. Haschek WM, Rousseaux CG 1998. Cardiovascular and skeletal muscle systems. In WM Haschek, CG Rousseaux, Fundamentals of toxicologic pathology, Academic Press, New York, USA, p. 309-335.
16. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ 1951. Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.
17. Masana M, de Toranzo EG, Castro JA 1984. Reductive metabolism and activation of benznidazole. Biochem Pharmacol 33: 1041-1045.
18. McGuire JJ, Anderson DJ, McDonald BJ, Narayanasami R, Bennett BM 1998. Inhibition of NADPH cytochrome P450 reductase and glyceryl trinitrate biotransformation by diphenyleneiodonium sulfate. Biochem Pharmacol 56: 881-893.
19. Pinto Dias JC 2000. Epidemiología. In Z Brener, Z Andrade, MT Barral-Netto. Trypanosoma cruzi e doença de Chagas, 2nd ed., Guanabara Koogan, Rio de Janeiro, Brasil, p. 48-74.
20. Pinto Dias JC, Silveira AC, Schofield CJ 2002. The impact of Chagas disease control in Latin America. A review. Mem Inst Oswaldo Cruz 97: 603-612.
21. Reyes PA, Vallejo M 2005. Trypanocidal drugs for late stage, symptomatic Chagas disease (Trypanosoma cruzi infection). Cochrane Database Syst Rev 19: CD004102.
22. Sosa-Estani S, Segura EL 2006. Etiological treatment in patients infected by Trypanosoma cruzi: experience in Argentina. Curr Opin Infect Dis 19: 583-587.
23. Viotti R, Vigliano C, Armenti A, Segura E 1994. Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am Heart J 127: 151-162.
24. Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, Postan M, Armenti A 2006. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment. Ann Intern Med 144: 724-734.
25. Wen JJ, Yachelini PC, Sembaj A, Manzur RE, Garg NJ 2006. Increased oxidative stress is correlated with mitochondrial dysfunction in chagasic patients. Free Radic Biol Med 41: 270-276.